News and Press - T1D Fund: A Breakthrough T1D Venture

The T1D Fund Announces Daniel McNamara as Head of Strategy & Industry Engagement to Grow the T1D Fund Brand and Drive Greater Interest in T1D Investments

May 13, 2025 | BOSTON, Mass.

Zucara Therapeutics Announces Second and Final Closing of US$25 Million Series B Financing

May 01, 2025 | Toronto, Canada

Mozart Therapeutics Completes Ph1a Study in Healthy Adults; Data Shows MTX-101 is Well Tolerated and Selectively Activates CD8 Treg

March 17, 2025

Egle Therapeutics Strengthens its Executive Leadership Team With the Appointment of Christophe Quéva, Ph.D., as Chief Executive Officer

January 15, 2025 | Paris, France

The T1D Fund Appoints Industry Veteran Elizabeth Mily as CEO to Accelerate Development of Type 1 Diabetes Cures Through Impact Investing

January 08, 2025 | BOSTON, Mass.